Grants for Public housing authorities - Health

The National Institute of Diabetes and Digestive and Kidney Disorders (NIDDK) intends to promote a new initiative by publishing a Notice of Funding Opportunity (NOFO) to solicit applications for the TrialNet Clinical Network Hub (HUB). The purpose of this Notice of Funding Opportunity (NOFO) is to continue support for the Type 1 Diabetes TrialNet Clinical Network Hub (HUB), a screening and clinical activities coordination unit for clinical trials focusing on the prevention of and early intervention in type 1 diabetes (T1D). The main objective of the HUB is to increase the efficiency and productivity of the TrialNet network by providing coordination of communications and outreach and developing new tools and approaches to increase screening, recruitment and retention. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The NOFO is expected to be published in Spring 2024 with an expected application due date in Summer 2024. This NOFO will utilize the U01 activity code. Details of the planned NOFO are provided below.

This grant provides funding to support diverse postdoctoral researchers in transitioning to independent faculty positions while conducting innovative research on pain and substance use disorders.

The purpose of this notice of funding opportunity (NOFO) is to support investigators who will form large, electronically-generated cohorts in Latin America of HIV-negative men who have sex with men (MSM), transgender women (TGW), people who inject drugs (PWID), and/or female sex-workers and follow them to study the epidemiology of HIV incidence. Continued follow-up of those persons who acquire HIV will be required to study the epidemiology of viral suppression. Comparisons of participants by seroconverstion status will provide information on geographic and socially defined areas of high HIV incidence as well as on both personal and structural vulnerabilities to HIV infection. Among participants who seroconvert, comparisons of those becoming rapidly engaged in care and who reach non-detectable HIV levels to those whose virus remains detectable will inform on the treatment of HIV in Latin American countries. This NOFO will allow digital trials to determine optimal study approaches, or to pilot evidence-based digital (mHealth and online) HIV prevention and treatment interventions to both reduce HIV incidence and improve treatment in the most vulnerable populations.Letter of Intent Due Date(s) 30 days prior to the application due date

This funding opportunity supports researchers conducting early-stage clinical trials for neurological disorders, focusing on innovative treatments and therapies that could lead to future efficacy studies.

This funding opportunity provides financial support to organizations in Sierra Leone to develop and implement community-led monitoring systems that improve the quality and accessibility of HIV services for key populations.

This funding opportunity supports researchers developing and testing behavioral interventions for drug abuse treatment, including those addressing comorbidities and utilizing technology to improve outcomes.

This funding opportunity supports the development and testing of cancer-related interventions through real-world clinical trials, particularly targeting diverse populations and addressing health disparities in the United States.

This funding opportunity supports collaborative clinical studies on mental illness across multiple research sites, encouraging diverse participation and innovative research into genetics, biomarkers, and treatment responses.

This Notice of Intent to Publish is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects for the following Notice of Funding Opportunity (NOFO), which is expected to be published in January 2024, with an anticipatedapplication receipt date in May 2024. The Brain Research through Advancing Innovative Neurotechnologies(BRAIN) Initiative intends to promote a new initiative by publishing a NOFO to solicit applications that would support development and preclinical testing, beginning withproof of concept,of next-generation recording and/or modulation devices for human use to further our understanding of the human central nervous system and treat nervous system disorders. This NOFO will utilize the R18 activity code. Details of the planned NOFO are provided below.

This funding opportunity invites researchers to develop and apply advanced imaging techniques to better understand the role of inflammation in cancer, fostering collaboration between cancer scientists and imaging experts.

This funding opportunity supports research training for underrepresented students and health professionals in cardiovascular, pulmonary, hematologic diseases, and sleep disorders, aiming to increase diversity in the biomedical research workforce and reduce health disparities.

This Funding Opportunity Announcement (FOA) allows for renewal and competitive revision applications, and their resubmissions, for funded U24?Research Resource/Infrastructure?applications?that?support?large-scale, complex research programs focused on?Alzheimers disease (AD) and?Alzheimers disease-related dementias (ADRD).?It is anticipated that such programs will likely involve a team of investigators within a single institution or a consortium of?institutions?and?align with one or more?AD/ADRD implementation research milestones?supporting the?research goals of the??National Plan to Address Alzheimers and Related Dementias.

The purpose of the NIDA Animal Genetics Program is to identify genetic, genomic, and molecular (epi)genetic variants that underlie: 1. Phenotypes associated with addictive behaviors and/or vulnerability to distinct stages along the substance use disorder (SUD) trajectory (e.g. initial/acute use, escalation of use, acquisition of tolerance, dependence, uncontrolled use, abstinence and relapse or recovery); 2. Behaviors associated with SUD (e.g. impulsivity, novelty seeking, delayed discounting, and other genetically-associated phenotypes); and 3. Comorbidities that demonstrate genetic correlations with phenotypes and behaviors linked with SUD (e.g. anxiety, stress, poor maternal care, social defeat, and other paradigms). Applications may examine any type of variant, including single nucleotide variants (SNVs), indels, large and small structural variants, and all types of mobile DNA. NIDA encourages applications that take genomics, multi-omics, and/or data-based approaches that integrate multi-level omics data, delineate gene networks, and/or uncover the function of known or newly discovered genetic or epigenetic variants. NIDA expects these studies to uncover novel mechanisms that contribute to SUD and facilitate the discovery of targets for intervention and guide the development of individualized therapeutics to treat these different aspects of SUD.

This funding opportunity provides financial support for research and evaluation projects aimed at improving malaria control and prevention strategies in Kenya, specifically targeting collaborations with local health institutions.

This funding opportunity provides financial support to early-career researchers who have received specific NIAMS awards, enabling them to conduct small-scale studies and gather data to advance their research and secure future funding.

This funding opportunity supports research to develop and test behavioral interventions aimed at reducing sexual risk behaviors and increasing the use of HIV prevention methods among HIV-negative Black and Hispanic men who have sex with men and use substances before or during sex.

This funding opportunity provides support for the development and management of early-phase cancer prevention clinical trials, focusing on evaluating interventions to reduce cancer risk across various organ sites.

The "Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research" grant aims to fund exploratory research projects that focus on improving the quality of cancer samples through the development and validation of innovative technologies, which will help in preserving sample integrity, establishing quality control, and reducing variations in sample quality, ultimately enhancing cancer research, diagnosis, and treatment.

This funding opportunity supports researchers in conducting single-site clinical trials focused on heart, lung, and blood health, encouraging innovative trial designs and community engagement.

The "HEAL Initiative: Understanding Individual Differences in Human Pain Conditions" grant aims to fund research that explores the differences in how individuals experience pain, with the goal of improving personalized pain treatment strategies and understanding the impact of factors like additional health conditions or substance use.